Bajaj Finserv Healthcare Fund - Growth - Direct Plan

Other Plans and Options
  • 0.02 %Nav, as on 30-04-2025

  • Previous Nav

  • Net Change on 30-04-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
BSE Health Care - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - Growth Jan 01, 2013 16.48 21.09 23.61 0.91 8,080.97
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Direct Plan - Cumulative Option Jul 13, 2018 21.76 25.25 26.16 1.18 4,914.64
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH Jan 01, 2013 21.90 25.15 25.76 0.90 3,610.51
DSP Healthcare Fund - Direct Plan - Growth Nov 30, 2018 15.73 21.37 25.63 0.63 3,018.76
Mirae Asset Healthcare Fund Direct Growth Jul 02, 2018 18.66 20.17 24.10 0.61 2,667.40

Fund Holdings as on 31-March-2025

  • Divi's Laboratories Limited

  • Sun Pharmaceutical Industries Limited

  • Dr. Reddy's Laboratories Limited

  • Cipla Limited

  • Apollo Hospitals Enterprise Limited

  • Net Receivables / (Payables)

  • Biocon Limited

  • Piramal Pharma Limited

  • Clearing Corporation of India Ltd

  • Syngene International Limited

  • Neuland Laboratories Limited

  • Torrent Pharmaceuticals Limited

  • Emcure Pharmaceuticals Limited

  • IPCA Laboratories Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Rainbow Childrens Medicare Limited

  • Hindustan Unilever Limited

  • Glenmark Pharmaceuticals Limited

  • Sanofi Consumer Healthcare India Limited

  • Abbott India Limited

  • Vijaya Diagnostic Centre Limited

  • Zydus Wellness Limited

  • Orchid Pharma Limited

  • Pfizer Limited

  • Alkem Laboratories Limited

  • Emami Limited

  • Lupin Limited

  • AstraZeneca Pharma India Limited

  • Alembic Pharmaceuticals Limited

  • Dr. Lal Path Labs Limited

  • Mankind Pharma Limited

  • Marico Limited

  • MedPlus Health Services Limited

  • Jubilant Pharmova Limited

  • Medi Assist Healthcare Services Limited

  • Colgate Palmolive (India) Limited

  • Shaily Engineering Plastics Limited

  • Neogen Chemicals Limited

  • Dr. Reddy's Laboratories Limited April 2025 Future

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Household & Personal Products

  • Business Support

  • Consumer Food

  • Plastic Products

  • Chemicals

View More

Fund Manager

  • Cash

  • Derivatives

  • Equity

View More

About Bajaj Finserv Healthcare Fund

Scheme Analysis

Bajaj Finserv Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Bajaj Finserv Mutual Fund. It was launched on 27-Dec-2024 and currently has an AUM of ₹307.40 crore. Bajaj Finserv Healthcare Fund is benchmarked against BSE Health Care - TRI as primary index.

The NAV of Bajaj Finserv Healthcare Fund ended up ₹0(0.02%)yesterday to ₹9.279.

Among its top 3 holdings the fund has exposure to Divi's Laboratories Limited, and

The Bajaj Finserv Healthcare Fund is managed by Nimesh Chandan and Siddharth Chaudhary.

Fund House Contact

S. No. 208/1B, Lohagaon Viman Nagar Pune - 411014

1800-309-3900
service@bajajamc.com
020-67672550